Unavailability of 50- and 75-mg oral etoposide in lung cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 4, 1996, Pages 327-331

  Fujiwara, Yasuhiro ^a   Ohune, Terumasa ^a   Okusaki, Ken ^a   Niitani, Kenji ^a   Sumiyoshi, Hidetaka ^a   Takemoto, Yuji ^a   Yamaoka, Naoki ^a   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Bioavailability; Etoposide

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG URINE LEVEL; FEMALE; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; RELAPSE;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL AVAILABILITY; CAPSULES; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HALF-LIFE; HUMANS; JAPAN; LUNG NEOPLASMS; MIDDLE AGED;

EID: 0030052559     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050392     Document Type: Article

References (23)

1. Hainsworth JD, Johnson DH, Redlin S, Frazier SR, Greco FA (1989) Chronic daily administration of oral etoposide- a phase I trial. J Clin Oncol 7:396-401
2. Johnson DH, Greco KA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613-1617
3. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA (1992) Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 10:292-296
4. D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera CJ, Rocchetti M, Pisoni MB, Piazza E, Beer M, Cavalli F (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7:141-145
5. Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J (1985) Bioavailabilily, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69:269-273
6. Smyth RD, Preffer M, Scalzo A, Comis RL (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12:48-51 [Suppl 2]
7. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PFM (1985) Variable bioavailabilily following repeated oral doses of etoposide.Eur J Cancer Clin Oncol 21:1315-1319
8. Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM (1986) The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16:178-181
9. Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ, Wrigley PFM (1989) The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331
10. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377
11. Ohune T, Fujiwara Y, Sumiyoshi H, Yamaoka N, Yamakido M (1995) Phase I and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer. Jpn J Cancer Res 86 490-500
12. Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM (1985) The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br J Cancer 52:363-367
13. Allen LM (1980) Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D- glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci 69:1440-1441
14. Yamaoka K., Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547-558
15. Clark PI, Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223-252
16. Joel SP, Dolega-Ossowski E, Jones K, Clark PI, Johnson P, Slevin ML (1991) The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose (abstract 1061). Proc Am Assoc Cancer Res 32: 178
17. Cavalli F, Zucchetti D, Gentili D, Pagani O, Marzola M, de Jong J, D'Incalci M, Sessa C (1992) Phase I and clinical pharmacological evaluation of daily oral etoposide (VP16) (abstract 257). Proc Am Soc Clin Oncol 11: 109
18. Relling MV, Nemee J, Schuetz FZ, Sehetz JD, Gonzalez FJ, Korzeka KR (1994) O-Demethylation of epipodophyllotoxin is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358
19. Baker DK, Relling MV, Pui C-H, Christensen ML, Evans WE, Rodman JH (1992) Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10:311-315
20. Waziers I de, Cugnenc PH, Yang CS, Leroux JP, Beaune PH (1990) Cytochrome P 450 isozymes, epoxidc hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878
22. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkin PB (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335:11-15
23. Kolars JC, Awni WM, Merion RM, Walkin PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490